After President Trump signed an order prohibiting Broadcom's (AVGO) attempt to take over Qualcomm (QCOM), Benchmark analyst Gary Mobley said the news may cause investors to question CFIUS approval for the planned tie-up of Marvell (MRVL) with Cavium (CAVM). It is possible Marvell may have to re-domicile in the U.S. from Bermuda, which may delay the merger by a few months and would increase Marvell's tax rate unfavorably, he said. Mobley, who think it is hard to say whether the President will shoot down the deal, noted that CFIUS and China's MOFCOM are the last two regulatory hurdles for Marvell and Cavium's deal. He has a Buy rating on Marvell shares.

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) initiated with an Outperform at Evercore ISI. 2. Caesars (CZR) initiated with an Overweight at JPMorgan. 3. e.l.f. Beauty (ELF) initiated with an Outperform at Oppenheimer. 4. uniQure (QURE) initiated with a Buy at SunTrust. 5. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Piper Jaffray analyst Harsh Kumar sees $10M-$15M of upside potential to Street revenue expectations for Marvell Technology's April quarter. The company reports Q1 results on May 31. The networking and storage markets are seeing "extremely strong, industry-wide trends," and Marvell is taking share in SSD, HDD, and networking, Kumar tells investors in a pre-earnings research note. Further, given the momentum in the higher margin segments, the analyst believes there is margin and earnings upside in the April quarter. For the July quarter guidance, Kumar is "extremely comfortable" with his slightly above consensus estimates. He continues to like shares of Marvell, and believes investors are waiting for MOFCOM approval in order to become more positive. The analyst keeps an Overweight rating on the name with a $28 price target.